Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 1/20 | 0.60 |
| ▸ | LTA4H | P09960 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1472793 | 0.96 | FKBP1A (0.64) | FKBP1ALTA4HCYP3A4KMT2AKDM4E | |
| SCHEMBL13248928 | 0.96 | FKBP1A (0.64) | FKBP1ALTA4HCYP3A4KMT2AKDM4E | |
| SCHEMBL1472792 | 0.96 | FKBP1A (0.64) | FKBP1ALTA4HCYP3A4KMT2AKDM4E | |
| SCHEMBL23043376 | 0.94 | FKBP1A (0.53) | FKBP1ACYP3A4KMT2AKDM4EALDH1A1 | |
| SCHEMBL9347282 | 0.94 | FKBP1A (0.53) | FKBP1ACYP3A4KMT2AKDM4EALDH1A1 | |
| SCHEMBL5965409 | 0.90 | FKBP1A (0.56) | FKBP1ACYP3A4KMT2AKDM4EALDH1A1 | |
| SCHEMBL15406170 | 0.90 | FKBP1A (0.56) | FKBP1ACYP3A4KMT2AKDM4EALDH1A1 | |
| SCHEMBL6223679 | 0.88 | LMNA (0.48) | FKBP1AKMT2AALDH1A1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL1471099 | 0.87 | LMNA (0.47) | FKBP1AKMT2AALDH1A1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL1471103 | 0.87 | LMNA (0.47) | FKBP1AKMT2AALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1805158-B1 | SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR | KALYPSYS INC (US) | 2018-06-27 | — | — | EP | disclosed |
| US-7915253-B2 | 4-[2,6-Dimethyl-4-(4-trifluoromethoxy-phenyl)-piperazine-1-sulfonyl]-indan-2-carboxylic acid; peroxisome proliferator activated receptors modulator; antidiabetic, antiinflammatory agent; obesity, hyperinsulinemia, metabolic syndrome X, polycystic ovary syndrome, ischemia-associated organ injury | KALYPSYS, INC (US) | 2011-03-29 | — | — | US | disclosed |
| US-7834004-B2 | Sulfonyl-substituted bicyclic compounds as modulators of PPAR | KALYPSYS, INC (US) | 2010-11-16 | — | — | US | disclosed |
| US-20090264417-A1 | SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR | KALYPSYS, INC. (US) | 2009-10-22 | — | — | US | disclosed |
| US-20090227599-A1 | SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR | KALYPSYS, INC. (US) | 2009-09-10 | — | — | US | disclosed |
| US-7517884-B2 | {5-[4-(4-Trifluoromethyl-phenyl)-piperazine-1-sulfonyl]-indan-2-yl}-acetic acid; peroxisome proliferator activated receptors modulator; antidiabetic, antiinflammatory agent; obesity, hyperinsulinemia, metabolic syndrome X, polycystic ovary syndrome, ischemia-associated organ injury, diabetes | KALYPSYS INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-7494999-B2 | Sulfonyl-substituted bicyclic compounds as modulators of PPAR | KALYPSYS, INC (US) | 2009-02-24 | — | — | US | disclosed |
| US-20090029971-A1 | SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR | KALYPSYS, INC. (US) | 2009-01-29 | — | — | US | disclosed |
| US-20060205736-A1 | Sulfonyl-substituted bicyclic compounds as modulators of PPAR | KALYPSYS, INC. | 2006-09-14 | — | — | US | disclosed |
| US-20060167012-A1 | Sulfonyl-substituted bicyclic compounds as modulators of PPAR | KALYPSYS, INC. | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167012-A1 | Sulfonyl-substituted bicyclic compounds as modulators of PPAR | PPARG, PPARA, PPARD | FKBP1A 2084/4885LTA4H 2936/4885CYP3A4 1506/4885 |
| US-20090029971-A1 | SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR | PPARG, PPARA, PPARD | FKBP1A 2084/4885LTA4H 2936/4885CYP3A4 1506/4885 |
| US-20090227599-A1 | SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR | PPARG, PPARA, PPARD | FKBP1A 2084/4885LTA4H 2936/4885CYP3A4 1506/4885 |
| US-20060205736-A1 | Sulfonyl-substituted bicyclic compounds as modulators of PPAR | PPARG, PPARA, PPARD | FKBP1A 2084/4885LTA4H 2936/4885CYP3A4 1506/4885 |
| US-20090264417-A1 | SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR | PPARG, PPARA, PPARD | FKBP1A 2084/4885LTA4H 2936/4885CYP3A4 1506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.